On November 5, Edwards Lifesciences rose 3.27% in Regular Trading, trading at $103.03 per share, with turnover of $48.06 million.
The move followed stronger-than-expected third-quarter results and a same-day price target increase from Piper Sandler to $115 from $101.
Edwards Lifesciences reported adjusted EPS of $0.80 for the third quarter, above the $0.74 consensus, on revenue of $1.72 billion versus the $1.68 billion expectation. For the fourth quarter, the company guided to adjusted EPS of $0.61 to $0.69 on revenue of $1.67 billion to $1.75 billion, while its full-year adjusted EPS outlook was narrowed to $2.97 to $3.05 from $2.95 to $3.05 previously. Separately, the stock’s average analyst rating remained overweight, and the mean price target moved up to $111.04.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments